Drug & intervention

cobimetinib

RxCUI 1722365

Clinical trials17
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

17 shown
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.NCT05768178 · 2023-03-01
RECRUITING
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic DisordersNCT04079179 · 2021-04-19
RECRUITING
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)NCT04302025 · 2020-11-06
RECRUITING
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid TumorsNCT04190628 · 2020-06-16
TERMINATED
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCNCT03989115 · 2019-07-02
COMPLETED
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung CancerNCT03600701 · 2018-11-29
ACTIVE_NOT_RECRUITING
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerNCT03566485 · 2018-07-10
TERMINATED
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)NCT03337698 · 2017-12-27
TERMINATED
Pre-operative Immunotherapy Combination Strategies in Breast CancerNCT03395899 · 2017-12-21
COMPLETED
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03178552 · 2017-09-22
ACTIVE_NOT_RECRUITING
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCNCT03202940 · 2017-09-14
ACTIVE_NOT_RECRUITING
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerNCT03202316 · 2017-08-11
ACTIVE_NOT_RECRUITING
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsNCT02457793 · 2015-06-16
COMPLETED
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadNCT02322814 · 2015-03-12
TERMINATED

Conditions being studied

Breast Cancer3Non-small Cell Lung Cancer3Anatomic Stage IV Breast Cancer AJCC v82Carcinoma, Non-Small-Cell Lung2Erdheim-Chester Disease2Stage II Pancreatic Cancer AJCC v82Stage III Pancreatic Cancer AJCC v82Stage IV Pancreatic Cancer AJCC v82Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Breast Carcinoma1Advanced Malignant Solid Neoplasm1Advanced Ovarian Carcinoma1Advanced Pancreatic Carcinoma1Advanced Prostate Carcinoma1Advanced Sarcoma1Advanced Solid Tumor1Anatomic Stage III Breast Cancer AJCC v81Anemia1Ann Arbor Stage III Hodgkin Lymphoma1Ann Arbor Stage III Non-Hodgkin Lymphoma1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.